Trabectedin-a targeted chemotherapy?

Lancet Oncology

Volumn 8, Issue 7, 2007, Pages 565-567

  von Mehren, Margaret ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOSINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; GUANINE; IMATINIB; TRABECTEDIN; TROGLITAZONE;

BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; EXCISION REPAIR; GASTROINTESTINAL TUMOR; HUMAN; LETTER; LUNG METASTASIS; MYXOSARCOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS INHIBITION; SOFT TISSUE METASTASIS; SOFT TISSUE SARCOMA; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; VISCERAL METASTASIS;

ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; DISEASE-FREE SURVIVAL; HUMANS; LIPOSARCOMA, MYXOID; ONCOGENE PROTEINS, FUSION; TETRAHYDROISOQUINOLINES;

EID: 34347212125     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70181-X     Document Type: Letter

References (12)

1. Elias A., Ryan L., Sulkes A., Collins J., Aisner J., and Antman K. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 7 (1989) 1208-1216
2. von Mehren M., and Watson J. Gastrointestinal stromal tumors. Hematol Oncol Clin North Am 19 (2005) 547-564
3. Grosso F., Jones R., Demetri G., et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8 (2007) 595-602
4. Patel S., Burgess M., Plager C., Papadpoulos M., Linke K., and Benjamin R. Myxoid liposarcoma. Experience with chemotherapy. Cancer 74 (1994) 1265-1269
5. Kuroda M., Ishida T., Takanashi M., Satoh M., Machinami R., and Watanabe T. Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Am J Pathol 151 (1997) 735-744
6. Perez-Mancera P., Perez-Losada J., Sanchez-Martin M., et al. Expression of the FUS domain restores liposarcoma development in CHOP transgenic mice. Oncogene 21 (2002) 1679-1684
7. Pommier Y., Kohlagen G., Bailly C., Waring M., Mazumder A., and Kohn K. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35 (1996) 13303-13309
8. Zewail-Foote M., Ven-Shun L., Kohn H., Bearss D., Guzman M., and Hurley L. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem Biol 8 (2001) 1033-1049
9. Delaloge S., Yovine A., Taamma A., et al. Ectinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patients- preliminary evidence of activity. J Clin Oncol 19 (2001) 1248-1255
10. Huygh G., Clement P., Dumez H., et al. Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma 2006 (2006) 56282
11. Le Cesne A., Blay J., Judson I., et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23 (2005) 576-584
12. Garcia-Carbonero R., Supko J., Manola J., et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22 (2004) 1480-1490